Prilenia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Prilenia Therapeutics's estimated annual revenue is currently $6M per year.
- Prilenia Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Prilenia Therapeutics has 39 Employees.
- Prilenia Therapeutics grew their employee count by -11% last year.
Prilenia Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Head Medical Affairs | Reveal Email/Phone |
4 | VP, Head Commercial | Reveal Email/Phone |
5 | Head Corporate Communications | Reveal Email/Phone |
6 | Controller and Finance manager | Reveal Email/Phone |
7 | Head Human Resources (Consultant) | Reveal Email/Phone |
8 | VP, Head CMC | Reveal Email/Phone |
9 | VP, Head Clinical Operations | Reveal Email/Phone |
10 | VP, Head Global Market Access | Reveal Email/Phone |
Prilenia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.1M | 78 | 7% | $47.7M | N/A |
#2 | $6M | 39 | 18% | N/A | N/A |
#3 | $2.8M | 18 | 0% | N/A | N/A |
#4 | $1.9M | 12 | -29% | N/A | N/A |
#5 | $1350.2M | 8711 | 6% | N/A | N/A |
#6 | $1350.2M | 8711 | 6% | N/A | N/A |
#7 | $1350.2M | 8711 | 6% | N/A | N/A |
#8 | $6M | 39 | -11% | N/A | N/A |
#9 | $2.8M | 18 | 6% | N/A | N/A |
#10 | $15.5M | 100 | 4% | N/A | N/A |
What Is Prilenia Therapeutics?
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. The company is led by Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. Our lead asset is Pridopidine, a first-in-class drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington's disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
keywords:N/A
N/A
Total Funding
39
Number of Employees
$6M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Prilenia Therapeutics News
The Netherlands: Prilenia Therapeutics, a clinical stage biotechnology company focused on developing therapeutics to slow the progression of...
Prilenia is a clinical stage biotech startup founded in 2018 focused on the urgent mission to develop novel therapeutics to slow the progression...
... Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals,...
Other Companies in Herzliya
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.5M | 39 | 34% | $97.7M |
#2 | $5.1M | 44 | 5% | N/A |
#3 | $6.4M | 50 | 43% | N/A |
#4 | $8.4M | 52 | 44% | N/A |
#5 | N/A | 54 | -19% | N/A |